Literature DB >> 23682111

Mapping the future for pulmonary fibrosis: report from the 17th International Colloquium on Lung and Airway Fibrosis.

Luca Richeldi1, Harold R Collard, Roland M du Bois, Gisli Jenkins, Martin Kolb, Toby M Maher, Ganesh Raghu, Carlo Vancheri, Geoffrey J Laurent.   

Abstract

Pulmonary fibrosis is the ultimate outcome of various interstitial lung diseases, many of which have a dismal prognosis. Pulmonary fibrosis, therefore, represents a critical unmet medical need. Progress in research over the past 30 years has been encouraging. This work, which has been funded by governments, charitable trusts, industries and patient groups, has resulted in clinical trials testing novel drugs, giving hope to patients. In late September 2012, representatives from academia, industry and funding agencies met at the 17th International Colloquium on Airway and Lung Fibrosis to discuss state-of-the-art knowledge of pulmonary fibrosis. This manuscript summarises the outcomes of the meeting, highlighting the most relevant results and discoveries. It also attempts to provide a roadmap for future studies. It is hoped that such a roadmap may help interested parties to generate new research, which will be vital to continued progress. We are encouraged by the commitment expressed by all participants at this meeting and the shared vision of promoting future progress through international collaboration, the pooling of valuable resources, and the involvement of a new generation of physicians and scientists.

Entities:  

Mesh:

Year:  2013        PMID: 23682111     DOI: 10.1183/09031936.00038613

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  8 in total

Review 1.  Idiopathic pulmonary fibrosis and a role for autoimmunity.

Authors:  Gerard F Hoyne; Hannah Elliott; Steven E Mutsaers; Cecilia M Prêle
Journal:  Immunol Cell Biol       Date:  2017-03-30       Impact factor: 5.126

2.  Earthworm extract attenuates silica-induced pulmonary fibrosis through Nrf2-dependent mechanisms.

Authors:  Jingjin Yang; Ting Wang; Yan Li; Wenxi Yao; Xiaoming Ji; Qiuyun Wu; Lei Han; Ruhui Han; Weiwen Yan; Jiali Yuan; Chunhui Ni
Journal:  Lab Invest       Date:  2016-10-24       Impact factor: 5.662

3.  Effect of Xinjiang Uyghur Vernonia anthelmintica Willd Injection Treatment with Silicosis Fibrosis.

Authors:  Guitao Liu; Yingjia Liu; Lu Jin; Cuidong Li; Liping Nie; Yanhua Wei; Wenyu Wang; Yuhong Xu; Nuziguli Nusilaiti; Ping Hua; Xiujuan Li; Xiaohua Wang; Wenlong Wei; Hamulati Wufuer
Journal:  Biomed Res Int       Date:  2016-10-10       Impact factor: 3.411

Review 4.  Telomere Abnormalities in the Pathobiology of Idiopathic Pulmonary Fibrosis.

Authors:  Hasancan Bilgili; Adam J Białas; Paweł Górski; Wojciech J Piotrowski
Journal:  J Clin Med       Date:  2019-08-16       Impact factor: 4.241

5.  CircHIPK3 regulates pulmonary fibrosis by facilitating glycolysis in miR-30a-3p/FOXK2-dependent manner.

Authors:  Qi Xu; Demin Cheng; Guanru Li; Yi Liu; Ping Li; Wenqing Sun; Dongyu Ma; Chunhui Ni
Journal:  Int J Biol Sci       Date:  2021-06-04       Impact factor: 6.580

6.  MicroRNA profiling implicates the insulin-like growth factor pathway in bleomycin-induced pulmonary fibrosis in mice.

Authors:  Lisa Honeyman; Mark Bazett; Tomasz G Tomko; Christina K Haston
Journal:  Fibrogenesis Tissue Repair       Date:  2013-08-29

7.  BARD1 mediates TGF-β signaling in pulmonary fibrosis.

Authors:  Pierre-Alain André; Cecilia M Prêle; Sarah Vierkotten; Stéphanie Carnesecchi; Yves Donati; Rachel C Chambers; Jean-Claude Pache; Bruno Crestani; Constance Barazzone-Argiroffo; Melanie Königshoff; Geoffrey J Laurent; Irmgard Irminger-Finger
Journal:  Respir Res       Date:  2015-09-29

8.  Lung transplantation in telomerase mutation carriers with pulmonary fibrosis.

Authors:  Leann L Silhan; Pali D Shah; Daniel C Chambers; Laurie D Snyder; Gerdt C Riise; Christa L Wagner; Eva Hellström-Lindberg; Jonathan B Orens; Juliette F Mewton; Sonye K Danoff; Murat O Arcasoy; Mary Armanios
Journal:  Eur Respir J       Date:  2014-05-15       Impact factor: 16.671

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.